Advertisement

Drugs

, Volume 45, Supplement 3, pp 59–64 | Cite as

Safety and Tolerability of Fluoroquinolones

  • S. Ragnar Norrby
  • Paul S. Lietman
State-of-The-Art Presentations

Summary

Since their introduction in the mid-1980s, the fluoroquinolones have been administered to more than 100 million patients. Generally, adverse effects reported in association with the fluoroquinolones have been those that could have been predicted by previous experience with non-fluorinated derivatives and by animal toxicity studies. Examples of such adverse events are CNS-related toxicity, upper gastrointestinal tract reactions and phototoxicity. Some adverse experiences in animals, notably cartilage toxicity, have been of minimal clinical importance. This should lead to a re-evaluation of the possible paediatric indications for the fluoroquinolones.

With temafloxacin, which was withdrawn from clinical use in June 1992, new and serious adverse events were reported at a frequency of about 1 per 3500 patients treated. This frequency of adverse events is too low to be detected even in very careful analyses of phase III registration studies. Anaphylaxis, haemolytic anaemia and renal failure were the most striking adverse events reported with temafloxacin, and, in addition, hypoglycaemia and hepatic failure were reported. These reactions may be attributable to an immunological reaction in some patients. Because of the rarity of these reactions, they can be detected only by studies encompassing thousands of patients, usually during postmarketing surveillance. Safety monitoring of each new fluoroquinolone during its early clinical use is therefore recommended.

Keywords

Fluoroquinolones Ofloxacin Quinine Norfloxacin Nalidixic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baes H. Photosensitivity caused by nalidixic acid. Dermatologica 136: 61–64, 1968CrossRefGoogle Scholar
  2. Ball P. Adverse reactions and interactions of fluoroquinolones. Clinical and Investigative Medicine 12: 28–34, 1989PubMedGoogle Scholar
  3. Bednarczyk EM, Green JA, Nelson AD, Leisure GA, Little D, et al. Comparison of the effect of temafloxacin, ciprofloxacin, or placebo on cerebral blood flow, glucose, and oxygen metabolism in healthy subjects by means of positron emission tomography. Clinical Pharmacology and Therapeutics 50: 165–171, 1991PubMedCrossRefGoogle Scholar
  4. Birkett DA, Garrets M, Stenson CJ. Phototoxic bullous eruptions due to nalidixic acid. British Journal of Dermatology 81: 342–344, 1969PubMedCrossRefGoogle Scholar
  5. Burckhardt JE, Hill MA, Carlton WW, Kesterson JW. Histologic and histochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone. Veterinary Pathology 27: 162–170, 1990CrossRefGoogle Scholar
  6. Camargo EE, Sostre S, Sadzot B, Shafizue I, Szabo Z, et al. Global and regional cerebral metabolic rate of 2-[18F]fluoro-2-deoxy-D-glucose in the presence of ofloxacin, a gamma-aminobutyric acid receptor antagonist. Antimicrobial Agents and Chemotherapy 35: 648–652, 1991PubMedCrossRefGoogle Scholar
  7. Christ W, Lehnert T, Ulbrich B. Specific toxicologic aspects of the quinolones. Reviews of Infectious Diseases 10 (Suppl. 1): A141–146, 1988CrossRefGoogle Scholar
  8. Christie D, Diaz-Arauzo H, Cook JM. Antibody mediated platelet destruction by quinine, quinidine, and their metabolites. Journal of Laboratory and Clinical Medicine 112: 92–98, 1988PubMedGoogle Scholar
  9. Christie D, Weber RW, Mullen PC, Cook JM, Aster RH. Structural features of the quinidine and quinine molecules necessary for binding of drug-induced antibodies to human platelets. Journal of Laboratory and Clinical Medicine 104: 730–740, 1984PubMedGoogle Scholar
  10. Corrado ML, Struble WE, Peter C, Hoaglund V, Sabbaj J. Norfloxacin: review of safety studies. American Journal of Medicine 26 (Suppl. 6B): 22–26, 1987CrossRefGoogle Scholar
  11. Cukierski MA, Prahaläda S, Zacchei AG, Peter CP, Rodgers JD, et al. Embryotoxicity studies of norfloxacin in Cynomolgus monkeys: I. Teratology studies and norfloxacin concentrations in pregnant and non-pregnant monkeys. Teratology 39: 39–52, 1989Google Scholar
  12. Dodd PR, Davies LP, Watson WEJ, Nielsen B, Dyer JA, et al. Neurochemical studies on quinolone antibiotics: effects on glutamate, GABA and adenosine systems in mammalian CNS. Pharmacology and Toxicology 64: 404–411, 1989PubMedCrossRefGoogle Scholar
  13. Douidar SM, Snodgrass WR. Potential role of fluoroquinolones in pediatric patients. Reviews of Infectious Diseases 11: 878–889, 1989PubMedCrossRefGoogle Scholar
  14. Elliot HL, Trash DB. Intravascular coagulation induced by quinine. Scottish Medical Journal 24: 244–245, 1979Google Scholar
  15. Enginar N, Eroglu L. The effect of ofloxacin and ciprofloxacin on pentylenetetrazol-induced convulsions in mice. Pharmacology, Biochemistry and Behavior 39: 587–589, 1991CrossRefGoogle Scholar
  16. Forsgren A, Neringer R, Hansson C, Ode B. Lomefloxacin versus norfloxacin in the treatment of uncomplicated urinary tract infections: three-day versus seven-day treatment. 30th ICAAC. Abstract no. 997, 1990Google Scholar
  17. Giardina WJ, Assessment of temafloxacin neurotoxicity in rodents. American Journal of Medicine 91 (Suppl. 6A): 42S–44S, 1991PubMedCrossRefGoogle Scholar
  18. Gottschall JL, Elliot W, Lianos E, McFarland JG, Wolfmeyer K, et al. Quinine-induced immune thrombocytopenia associated with hemolytic uremic syndrome: a new clinical entity. Blood 77: 306–310, 1991PubMedGoogle Scholar
  19. Hooper DC, Wolfson JS. Mode of action of the new quinolones: new data. In Rubinstein E (Ed.) Proceedings of the 3rd International Symposium on New Quinolones. European Journal of Clinical Microbiology and Infectious Diseases (Special Issue): 3–11, 1991Google Scholar
  20. LeBel M. Fluoroquinolones in the treatment of cystic fibrosis: a critical appraisal. European Journal of Clinical Microbiology and Infectious Diseases 10: 316–324, 1991CrossRefGoogle Scholar
  21. McQueen CA, Way BM, Queener SM, Schlüter G, Williams GM. Study of potential in vitro and in vivo genotoxicity in hepatocytes of quinolone antibiotics. Toxicology and Applied Pharmacology 111: 255–262, 1991PubMedCrossRefGoogle Scholar
  22. Norrby SR, Pernet AH. Assessment of adverse events during drug development: experience with temafloxacin. Journal of Antimicrobial Chemotherapy 28 (Suppl. C): 111–119, 1992Google Scholar
  23. Paton JH, Reeves DS. Clinical features and management of adverse effects of quinolone antibiotics. Drug Safety 6: 8–17, 1991PubMedCrossRefGoogle Scholar
  24. Percival A. Impact of chemical structure on quinolone potency, spectrum and side effects. Journal of Antimicrobial Chemotherapy 28 (Suppl. C): 1–8, 1992Google Scholar
  25. Pernet AG. Temafloxacin: a safe antibiotic for the elderly, patients with comorbidities, and other special populations. American Journal of Medicine 91 (Suppl. 6A): 162–165, 1991CrossRefGoogle Scholar
  26. Pertuiset E, Lenoir G, Jehanne M, Douchain F, Guillot M, et al. Tolérance articulaire de la péfloxacine et de l’ofloxacin chez les enfants et adolescents atteints de mucoviscidose. Revue du Rhumatisme et des Maladies Osteo-Articulaires 56: 735–740, 1989PubMedGoogle Scholar
  27. Ramsay CH, Obreshfova B. Phototoxicity from nalidixic acid. British Journal of Dermatology 91: 523–528, 1974PubMedCrossRefGoogle Scholar
  28. Robertson DG, Epling GA, Keily JS, Bailey DL, Song B. Mechanistic studies of the phototoxicity potential of PD 117596, a quinolone antibacterial compound. Toxicology and Applied Pharmacology 111: 221–232, 1991PubMedCrossRefGoogle Scholar
  29. Schaad UB, Wedgewood-Krucko J. Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity. Infection 15: 165–168, 1987PubMedCrossRefGoogle Scholar
  30. Spearing RL, Hickton CM, Sizeland P, Hannah A, Bailey R. Quinine induced disseminated intravascular coagulation. Lancet 336: 1535–1537, 1990PubMedCrossRefGoogle Scholar
  31. Specht TE, Frederick G. Quinolone-induced arthropathy in immature Equidae. Journal of the Veterinary Medical Association of America 198: 516, 1991Google Scholar
  32. Stahlmann R. Safety profile of the quinolones. Journal of Antimicrobial Chemotherapy 26 (Suppl. D): 31–44, 1990PubMedGoogle Scholar
  33. Stahlmann R. Knorpelschädigende Wirkung der Chinolone. Infection 19 (Suppl. 1): S38–46, 1991PubMedCrossRefGoogle Scholar
  34. Stroncek DF, Vercelotti GM, Hammerschmidt DE, Christie DJ, Shankara RA, et al. Characterization of multiple quinine-dependent antibodies in a patient with episodic hemolytic uremic syndrome and immune agranulocytosis. Blood 80: 241–248, 1992PubMedGoogle Scholar
  35. Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U. Possible interaction of fluoroquinolones with the benzodiazepine-GABAA-receptor complex. British Journal of Pharmacology 30: 63–70, 1990CrossRefGoogle Scholar
  36. Visentin GP, Newman PJ, Aster RH. Characteristics of quinine- and quinidine-induced antibodies specific for platelet glycoproteins IIb and IIIa. Blood 42: 2668–2676, 1991Google Scholar
  37. Wadworth AN, Goa KL. Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 42: 1018–1060, 1991Google Scholar
  38. Wagai N, Tawara K. Quinolone antibacterial-agent-induced cutaneous phototoxicity: ear swelling reaction in Balb/c mice. Toxicology Letters 58: 215–223, 1991aPubMedCrossRefGoogle Scholar
  39. Wagai N, Tawara K. Important role of oxygen metabolites in quinolone antibacterial agent induced cutaneous phototoxicity in mice. Archives of Toxicology 65: 495–499, 1991bPubMedCrossRefGoogle Scholar
  40. Wolfson JS. Overview of fluoroquinolone safety. American Journal of Medicine 91 (Suppl. 6A): 153–161, 1991CrossRefGoogle Scholar
  41. Ysern P, Clerch B, Castano M, Gibert I, Barbé J, et al. Induction of SOS genes in Escherichia coli and mutagenesis in Salmonella typhimurium by fluoroquinolones. Mutagenesis 5: 63–66, 1990PubMedCrossRefGoogle Scholar

Copyright information

© ADIS International Limited 1993

Authors and Affiliations

  • S. Ragnar Norrby
    • 1
  • Paul S. Lietman
    • 2
  1. 1.Department of Infectious DiseasesLund University HospitalLundSweden
  2. 2.Department of Clinical PharmacologyJohns Hopkins School of MedicineBaltimoreUSA

Personalised recommendations